Anti-NMI antibody [2C1] (STJA0032747)
SPECIFICATIONS
ClonalityMonoclonal
HostMouse
ConjugationUnconjugated
IsotypeIgG2b
ImmunogenPurified recombinant human NMI protein fragments expressed in E.coli.
General Information
| Short Description | Mouse monoclonal anti-NMI for use in WB in Human samples. Datasheet included with dilution recommendations, and related reagents. |
| Applications | WB |
| Host | Mouse |
| Reactivity | Human |
| Note | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Product Properties
| Clonality | Monoclonal |
| Clone ID | 2C1 |
| Isotype | IgG2b |
| Conjugation | Unconjugated |
| Concentration | 1 mg/mL |
| Purification | Affinity Purified |
| Dilution Range | WB 1:500-1:1000 |
| Formulation | Liquid in PBS containing 50% glycerol, 1% BSA and 0.02% sodium azide, pH 7.3. |
| Storage Instruction | Store at 4°C short term. Aliquot and store at-20°C long term. Avoid freeze/thaw cycles. |
Target Information
| Gene Symbol | NMI |
| Gene ID | 9111 |
| Uniprot ID | NMI_HUMAN |
| Immunogen | Purified recombinant human NMI protein fragments expressed in E.coli. |
Additional Info
| Tissue Specificity | Expressed in adult spleen, liver, and kidney. Expressed in fetal thymus, liver, placenta, spleen, lung, and kidney but not brain. Expressed in macrophages. |
| Post Translational Modifications | Ubiquitinated. 'Lys-63'-linked ubiquitination by TRIM21 promotes interaction with IFI35 and inhibits virus-triggered type I IFN-beta production. |
| Function | Acts as a signaling pathway regulator involved in innate immune system response. In response to interleukin 2/IL2 and interferon IFN-gamma/IFNG, interacts with signal transducer and activator of transcription/STAT which activate the transcription of downstream genes involved in a multitude of signals for development and homeostasis. Enhances the recruitment of CBP/p300 coactivators to STAT1 and STAT5, resulting in increased STAT1- and STAT5-dependent transcription. In response to interferon IFN-alpha, associates in a complex with signaling pathway regulator IFI35 to regulate immune response.the complex formation prevents proteasome-mediated degradation of IFI35. In complex with IFI35, inhibits virus-triggered type I IFN-beta production when ubiquitinated by ubiquitin-protein ligase TRIM21. In complex with IFI35, negatively regulates nuclear factor NF-kappa-B signaling by inhibiting the nuclear translocation, activation and transcription of NF-kappa-B subunit p65/RELA, resulting in the inhibition of endothelial cell proliferation, migration and re-endothelialization of injured arteries. Negatively regulates virus-triggered type I interferon/IFN production by inducing proteosome-dependent degradation of IRF7, a transcriptional regulator of type I IFN, thereby interfering with cellular antiviral responses. Beside its role as an intracellular signaling pathway regulator, also functions extracellularly as damage-associated molecular patterns (DAMPs) to promote inflammation, when actively released by macrophage to the extracellular space during cell injury or pathogen invasion. Macrophage-secreted NMI activates NF-kappa-B signaling in adjacent macrophages through Toll-like receptor 4/TLR4 binding and activation, thereby inducing NF-kappa-B translocation from the cytoplasm into the nucleus which promotes the release of pro-inflammatory cytokines. |
| Protein Name | N-Myc-InteractorNmiN-Myc And Stat Interactor |
| Database Links | Reactome: R-HSA-9692916 |
| Cellular Localisation | CytoplasmNucleusSecretedCytoplasmic Nmi Localizes In Punctate Granular StructuresNuclear Localization Increased Following Ifn-Alpha TreatmentExtracelullar Following Secretion By Macrophage |
| Alternative Antibody Names | Anti-N-Myc-Interactor antibodyAnti-Nmi antibodyAnti-N-Myc And Stat Interactor antibodyAnti-NMI antibody |
Information sourced from Uniprot.org